Home
HelpTest Code REVE2 Erythrocytosis Evaluation, Blood
Ordering Guidance
Polycythemia vera and acquired causes of erythrocytosis should be excluded before ordering this evaluation.
Necessary Information
Send the following information with the specimen:
-Recent transfusion information
-Most recent complete blood cell count (CBC) results and serum erythropoietin (EPO) levels, if known
Metabolic Hematology Patient Information (T810) is strongly recommended and should include clinical and family history, CBC results, EPO levels, and JAK2 testing results, if known. Testing may proceed without this information; however, it allows for a more complete interpretation.
Specimen Required
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD solution B), green top (sodium heparin)
Specimen Volume: 5 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
CMH COLLECTION: 3mL blood in a vacutainer Preferred: EDTA lavender Acceptable: Sodium heparin green Sendout lab will procure control sample
Useful For
Definitive, comprehensive, and economic evaluation of an individual with JAK2-negative erythrocytosis associated with lifelong sustained increased hemoglobin or hematocrit
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| REVEI | Erythrocytosis Interpretation | No | Yes |
| HGBCE | Hb Variant, A2 and F Quantitation,B | Yes | Yes |
| HPLC | HPLC Hb Variant, B | No | Yes |
| MASS | Hb Variant by Mass Spec, B | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SDEX | Sickle Solubility, B | Yes | No |
| HEMP | Hereditary Erythrocytosis Mut, B | Yes | No |
| IEF | Isoelectric Focusing, B | No | No |
| UNHB | Hb Stability, B | No | No |
| HPFH | Hb F Distribution, B | No | No |
| WASQR | Alpha Globin Gene Sequencing, B | Yes, (Order WASEQ) | No |
| WBSQR | Beta Globin Gene Sequencing, B | Yes, (Order WBSEQ) | No |
| WGSQR | Gamma Globin Full Gene Sequencing | Yes, (Order WGSEQ) | No |
| BPGMM | BPGM Full Gene Sequencing | Yes | No |
| REVE0 | Erythrocytosis Summary Interp | No | No |
| WAGDR | Alpha Globin Clustr Locus Del/Dup,B | Yes, (Order AGDD) | No |
| WBGDR | Beta Globin Gene Cluster, Del/Dup,B | Yes, (Order WBGDD) | No |
| VHLE | VHL Gene Erythrocytosis Mutations | No | No |
Testing Algorithm
This is a consultative evaluation in which the case will be evaluated at Mayo Clinic Laboratories, the appropriate tests will be performed at an additional charge, and the results interpreted.
This profile evaluates for hereditary (congenital) causes of erythrocytosis. Symptoms should be long-standing or familial in nature. All cases will be tested for hemoglobin variants (cation exchange high performance liquid chromatography, capillary electrophoresis, and mass spectrometry) with an interpretative report. Additional testing is guided in a reflexive manner and may include molecular testing of the HBA1/HBA2, HBB, EPOR, VHL, EGLN1(PHD2), EPAS1(HIF2a), and BPGM genes, among others, as appropriate. For more information see Erythrocytosis Evaluation Testing Algorithm.
If any of the following molecular tests are performed, an additional consultative interpretation that summarizes all testing will be provided to incorporate subsequent results into an overall evaluation:
-WAGDR / Alpha Globin Cluster Locus Deletion/Duplication, Blood
-WASQR / Alpha -Globin Gene Sequencing, Blood
-WBSQR / Beta-Globin Gene Sequencing, Blood
-WBGDR / Beta-Globin Gene Cluster Deletion/Duplication, Blood
-WGSQR / Gamma-Globin Full Gene Sequencing, Varies
Additional reflex tests are performed if the hemoglobin testing does not explain the patient's phenotype/hereditary erythrocytosis. Each of the following reflex tests contains an individual interpretative report.
-BPGMM / 2,3-Bisphosphoglycerate Mutase, Full Gene Sequencing Analysis, Varies
-HEMP / Hereditary Erythrocytosis Mutations, Whole Blood
-VHLE / VHL Gene, Erythrocytosis, Mutation Analysis, Varies
For more information, see:
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Special Instructions
- Informed Consent for Genetic Testing
- Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
- Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
- Erythrocytosis Evaluation Testing Algorithm
- Metabolic Hematology Patient Information
- Benign Hematology Evaluation Comparison
- Informed Consent for Genetic Testing (Spanish)
Method Name
REVEI, REVE0: Medical Interpretation
HGBCE: Capillary Electrophoresis
HPLC: Cation Exchange/High Performance Liquid Chromatography (HPLC)
MASS: Mass Spectrometry (MS)
IEF: Isoelectric Focusing
HPFH: Flow Cytometry
UNHB: Isopropanol and Heat Stability
VHLE: Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis
Reporting Name
Erythrocytosis EvaluationSpecimen Minimum Volume
2.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated | 7 days |
Reject Due To
| Gross hemolysis | Reject |
Reference Values
Definitive results and an interpretive report will be provided.
Day(s) Performed
Monday through Saturday
Report Available
3 to 25 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
83020-26
83020
83021
83789
83068 (if appropriate)
82664 (if appropriate)
88184 (if appropriate)